Drug intelligence / Profile preview

Marburg virus GP vaccine

Development stage: Preclinical
Lead developer: Hawaii Biotech
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics

Overview

**Marburg virus GP vaccine** is a preclinical recombinant protein subunit vaccine being developed by Hawaii Biotech for prevention of **Marburg virus disease**. The vaccine is designed around the **Marburg virus glycoprotein** antigen to elicit protective humoral and cellular immune responses against Marburg virus infection. Based on the company pipeline description, it is a **recombinant subunit protein vaccine** directed at Marburg GP and is part of Hawaii Biotech's broader filovirus vaccine portfolio.

Other names: Marburg virus glycoprotein vaccine

Targets

Marburg virus glycoprotein

Beyond the preview

Go deeper on Marburg virus GP vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marburg virus GP vaccine.

Explore the full profile